Immunovant Inc’s filing revealed that its Officer WILLIAM MACIAS acquired Company’s shares for reported $0.78 million on Jun 13 ’25. In the deal valued at $15.57 per share,50,000 shares were bought.
Then, WILLIAM MACIAS bought 80,000 shares, generating $1,248,616 in total proceeds.
Before that, GEORGE V MIGAUSKY bought 21,812 shares. Immunovant Inc shares valued at $318,047 were divested by the Former Director at a price of $14.58 per share.
Jefferies initiated its Immunovant Inc [IMVT] rating to a Hold in a research note published on March 03, 2025; the price target was $20. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in early January from “an Outperform” to “a Peer perform”. Oppenheimer maintained its rating on October 09, 2024. It rated IMVT as “an Outperform”.
Price Performance Review of IMVT
On Friday, Immunovant Inc [NASDAQ:IMVT] saw its stock fall -1.76% to $15.66. Over the last five days, the stock has lost -6.62%. Immunovant Inc shares have fallen nearly -36.78% since the year began. Nevertheless, the stocks have fallen -37.61% over the past one year. While a 52-week high of $34.47 was reached on 01/02/25, a 52-week low of $12.72 was recorded on 04/09/25.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 15.31, which if violated will result in even more drops to 14.97. On the upside, there is a resistance level at 16.04. A further resistance level may holdings at 16.43.
How much short interest is there in Immunovant Inc?
A steep rise in short interest was recorded in Immunovant Inc stocks on 2025-05-30, growing by 0.97 million shares to a total of 21.68 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 20.71 million shares. There was a rise of 4.47%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 28, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
